Transforming drug discovery with deep learning imputation
In European Biopharmaceutical Review, Optibrium’s CEO Dr Matthew Segall discusses how we can elevate drug discovery with deep learning imputation. He shares…
Optibrium appoints Ian Smith as Chief Technology Officer
New role will lead technology development as the Company continues to scale team and global business operations. Appointment of former Merck, Sharp and Dohme (MSD) Director of R&D Analytics supports continued innovation of Optibrium’s AI drug discovery software.
Optibrium expands operations in North America for AI and computational drug discovery technologies
Establishment of Optibrium Inc. bolsters ongoing strategic Company growth and strenghtens direct US customer support. Dr Tamsin Mansley promoted to President of Optibrium Inc. to lead growing US-based team and business operations.
Optibrium strengthens global AI drug discovery software operations with three key appointments
Michelle Harrison appointed as Head of Strategic Marketing; Chris Khoury and Imran Ghauri join to boost Optibrium’s business development team. UK and US-based appointments with proven AI and life science expertise will support the next phase of commercial growth for Optibrium’s computational drug discovery technologies.
Optibrium receives further investment from Kester Capital
Second round of funding from existing investors will further drive company expansion and commercial growth of its AI-enabled drug discovery technology.
Optibrium releases 3D ligand-based design module for StarDrop drug discovery software
Innovative predictive methods support virtual screening and compound design in the absence of 3D structure data.
